Isolated liver perfusion permits administration of high doses of chemotherapeutic agents: Comparison with hepatic artery infusion

European Surgical Research

Volumn 33, Issue 5-6, 2001, Pages 342-347

  Thorlacius, H ^a   Larmark, M ^b   Randell, M ^a   Hultberg, B ^a   Jeppsson, B ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acivicin; Glutamine; Liver; Local perfusion; Tumor

Indexed keywords

ACIVICIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLUTAMINE; HEMOGLOBIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HEPATIC ARTERY; INFUSION; INOCULATION; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER PERFUSION; LIVER TUMOR; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VOLUME;

EID: 0035704311     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049728     Document Type: Article

References (27)

1. The role of glutamine in the oxidative metabolism of malignant cells
2. Amino acid, glucose, and lactic acid utilization in vivo by rat tumors
3. Energy substrate utilization in freshly isolated Morris hepatoma 7777 cells
4. Glutamine and cancer
5. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines
6. Enzyme targets of antiglutamine agents in cancer chemotherapy
7. Biochemical pharmacology of acivicin in rat hepatoma cells
8. Acivicin reduces tumor growth during total parenteral nutrition (TPN)
9. Control of enzymatic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin
10. Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion
11. Negative correlation of L-glutamine concentration with proliferation rate in rat hepatomas
12. Acivicin: A new glutamine antagonist in clinical trials
13. A technique for isolated liver perfusion in the rat with survival and results of cytotoxic drug perfusion on liver tumor growth
14. Cross-reacting tumor-associated antigens among chemically induced rat colon carcinomas
15. Phase II study of acivicin in colorectal carcinoma: A National Cancer Institute of Canada study
16. Phase II trial of acivicin in patients with advanced colorectal carcinoma
17. Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma: A Gynecologic Oncology Group Study
18. Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: A Southwest Oncology Group trial
19. Phase II study of acivicin in non-small cell lung cancer: A National Cancer Institute of Canada study
20. Phase I study of acivicin and cisplatin in non-small cell lung cancer: A National Cancer Institute of Canada study
21. A phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies
22. Isolated hypoxic hepatic perfusion (IHHP) using ballon catheter techniques: From laboratory to the clinic towards a percutaneous procedure
23. Percutaneous isolated liver chemoperfusion for treatment of unresectable malignant liver tumors: Technique, pharmacokinetics, clinical results
24. Two-staged treatment with local resection and percutaneous isolated hepatic chemoperfusion for advanced pancreatic cancer with multiple liver metastasis: Reports of a case
25. Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II, and amidophosphoribosyltransferase in hepatoma
26. Gamma-glutamyl transpeptidase mediation of tumor glutathione utilization in vivo